



MEN

FIRST CANCER SITE
URINARY TRACT

URINARY TRACT
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

VIE URINARIE
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	3363		3797		3797		3363		2492		1079		408		3363	3797
Person-years ▶	13872		14466		594		2380		6581		3470		1442		13872	14466
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT URINARY TRACT	353	1.09	410	1.21	57	4.18	64	1.19	174	1.16	79	0.95	36	0.95	2.06	4.97
HEAD AND NECK	11	0.89	11	0.85	0	0.00	1	0.46	8	1.34	1	0.33	1	0.81	-0.10	-0.14
ORAL CAVITY	2	0.69	2	0.66	0	0.00	0	0.00	1	0.72	1	1.38	0	0.00	-0.07	-0.07
PHARYNX	2	0.78	2	0.75	0	0.00	0	0.00	2	1.63	0	0.00	0	0.00	-0.04	-0.05
LARYNX	7	1.01	7	0.96	0	0.00	1	0.82	5	1.50	0	0.00	1	1.46	0.00	-0.02
OESOPHAGUS	2	0.59	3	0.84	1	6.74	1	1.72	0	0.00	1	1.17	0	0.00	-0.10	-0.04
STOMACH	15	0.74	18	0.85	3	3.29	1	0.28	12	1.27	0	0.00	2	0.88	-0.38	-0.22
COLON RECTUM	52	1.16	54	1.16	2	1.07	7	0.96	23	1.12	16	1.38	6	1.11	0.52	0.51
COLON	34	1.10	36	1.12	2	1.56	5	1.00	17	1.21	8	0.99	4	1.04	0.22	0.26
RECTUM	18	1.31	18	1.26	0	0.00	2	0.87	6	0.94	8	2.28	2	1.27	0.31	0.25
LIVER	15	1.17	17	1.27	2	3.70	0	0.00	11	1.84	4	1.22	0	0.00	0.15	0.25
GALLBLADDER	4	1.12	4	1.07	0	0.00	3	5.06	0	0.00	0	0.00	1	2.28	0.03	0.02
PANCREAS	6	0.68	6	0.65	0	0.00	0	0.00	3	0.74	1	0.44	2	1.87	-0.21	-0.23
LUNG	73	1.28	83	1.39	10	4.07	8	0.83	34	1.28	24	1.67	7	1.09	1.15	1.62
SKIN MELANOMA	4	0.95	4	0.91	0	0.00	0	0.00	2	1.05	1	0.90	1	1.89	-0.01	-0.03
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.12	-0.12
KAPOSI SARCOMA	1	1.48	1	1.42	0	0.00	0	0.00	0	0.00	1	5.87	0	0.00	0.02	0.02
SOFT TISSUE	1	0.93	1	0.89	0	0.00	0	0.00	0	0.00	1	3.61	0	0.00	-0.01	-0.01
BONE	1	3.79	1	3.62	0	0.00	0	0.00	0	0.00	1	15.36	0	0.00	0.05	0.05
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
PROSTATE	78	1.20	102	1.51	24	9.32	18	1.76	34	1.16	17	0.99	9	1.12	0.95	2.39
TESTIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
KIDNEY AND RENAL PELVIS	5	0.51	11	1.08	6	15.03	4	2.51	1	0.22	0	0.00	0	0.00	-0.34	0.06
BLADDER AND URINARY TRACT	50	1.38	58	1.54	8	5.22	16	2.66	28	1.68	2	0.22	4	0.95	1.00	1.41
URINARY BLADDER	50	1.45	58	1.62	8	5.49	16	2.79	28	1.77	2	0.23	4	0.99	1.12	1.53
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.12	-0.12
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.29	1	0.28	0	0.00	0	0.00	0	0.00	1	1.16	0	0.00	-0.17	-0.18
THYROID	3	2.44	3	2.35	0	0.00	0	0.00	2	3.50	1	3.12	0	0.00	0.13	0.12
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	13	1.45	13	1.39	0	0.00	2	1.35	9	2.17	1	0.43	1	0.94	0.29	0.25
MYELOMA	4	0.92	4	0.89	0	0.00	1	1.38	3	1.51	0	0.00	0	0.00	-0.02	-0.04
LEUKAEMIAS	9	1.20	9	1.15	0	0.00	2	1.58	2	0.58	4	2.11	1	1.15	0.11	0.08
LYMPHOID LEUKAEMIAS	2	0.56	2	0.53	0	0.00	1	1.64	1	0.60	0	0.00	0	0.00	-0.11	-0.12
MYELOID LEUKAEMIAS	7	2.07	7	1.99	0	0.00	1	1.78	1	0.65	4	4.61	1	2.45	0.26	0.24
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OTHER AND ILL DEFINED SITES	5	0.29	6	0.33	1	1.34	0	0.00	2	0.26	2	0.45	1	0.47	-0.88	-0.83

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
URINARY TRACT

URINARY TRACT
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

VIE URINARIE
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	1341		1562		1562		1341		891		354		137		1341	1562
Person-years ▶	4837		5078		241		895		2219		1175		548		4837	5078
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT URINARY TRACT	72	1.14	86	1.30	14	4.39	17	1.47	31	1.09	15	0.97	9	1.18	1.85	3.89
HEAD AND NECK	1	1.29	1	1.22	0	0.00	0	0.00	0	0.00	0	0.00	1	10.84	0.05	0.04
ORAL CAVITY	1	2.27	1	2.16	0	0.00	0	0.00	0	0.00	0	0.00	1	18.66	0.12	0.11
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OESOPHAGUS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.07	-0.07
STOMACH	4	0.96	4	0.91	0	0.00	1	1.25	2	1.06	1	1.01	0	0.00	-0.03	-0.07
COLON RECTUM	15	1.46	16	1.48	1	1.91	3	1.59	7	1.52	3	1.19	2	1.57	0.97	1.02
COLON	12	1.61	12	1.53	0	0.00	1	0.74	7	2.10	3	1.63	1	1.07	0.94	0.82
RECTUM	3	1.06	4	1.35	1	6.89	2	3.82	0	0.00	0	0.00	1	2.96	0.04	0.20
LIVER	1	0.55	1	0.52	0	0.00	0	0.00	0	0.00	0	0.00	1	4.45	-0.17	-0.18
GALLBLADDER	1	0.67	1	0.64	0	0.00	0	0.00	0	0.00	1	2.80	0	0.00	-0.10	-0.11
PANCREAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.58	-0.58
LUNG	0	0.00	5	1.16	5	24.81	0	0.00	0	0.00	0	0.00	0	0.00	-0.85	0.14
SKIN MELANOMA	0	0.00	1	0.92	1	19.90	0	0.00	0	0.00	0	0.00	0	0.00	-0.21	-0.02
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	2	7.85	2	7.48	0	0.00	0	0.00	0	0.00	2	31.44	0	0.00	0.36	0.34
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	16	1.11	16	1.06	0	0.00	1	0.38	9	1.37	2	0.56	4	2.36	0.32	0.17
CERVIX UTERI	1	1.39	2	2.63	1	26.36	0	0.00	0	0.00	1	5.86	0	0.00	0.06	0.24
CORPUS UTERI	3	1.17	3	1.12	0	0.00	0	0.00	1	0.85	2	3.19	0	0.00	0.09	0.06
OVARY	1	0.54	2	1.02	1	10.66	0	0.00	0	0.00	0	0.00	1	4.62	-0.18	0.01
KIDNEY AND RENAL PELVIS	2	1.31	3	1.88	1	13.49	2	7.42	0	0.00	0	0.00	0	0.00	0.10	0.28
BLADDER AND URINARY TRACT	11	4.29	15	5.56	4	30.49	6	12.75	3	2.61	2	3.18	0	0.00	1.74	2.42
URINARY BLADDER	11	4.64	15	6.02	4	33.23	6	13.87	3	2.83	2	3.44	0	0.00	1.78	2.46
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
BRAIN AND CENTRAL NERVOUS SYSTEM	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.18	-0.18
THYROID	1	1.19	1	1.14	0	0.00	0	0.00	1	2.62	0	0.00	0	0.00	0.03	0.02
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	1	0.43	1	0.41	0	0.00	0	0.00	1	0.94	0	0.00	0	0.00	-0.28	-0.29
MYELOMA	1	0.88	1	0.83	0	0.00	0	0.00	1	1.94	0	0.00	0	0.00	-0.03	-0.04
LEUKAEMIAS	1	0.60	1	0.58	0	0.00	0	0.00	0	0.00	1	2.48	0	0.00	-0.14	-0.15
LYMPHOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.15	-0.15
MYELOID LEUKAEMIAS	1	1.30	1	1.23	0	0.00	0	0.00	0	0.00	1	5.25	0	0.00	0.05	0.04
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	10	1.94	10	1.84	0	0.00	4	4.16	6	2.61	0	0.00	0	0.00	1.00	0.90

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio